Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

CELLINK has entered an agreement to acquire single-cell dispensing company cytena GmbH.

CELLINK AB ("CELLINK") has entered an agreement with the owners of cytena GmbH ("cytena") to acquire all cytena shares for a purchase price of 30.25M euros ("acquisition"). Through cytena's complementary technology offering, CELLINK sees great synergies that will support future growth. cytena is the company CELLINK announced signing a LOI with in conjunction with raising capital in June this year. About cytena cytena is a life science company focusing on single-cell technologies. cytena was founded in 2014 within the Institute for Microsystems Technology (IMTEK) at the University of

Presentation of Polygon second quarter 2019 report

On Friday August 9, 2019 at 08.00 CET, Polygon AB (publ) will publish its second quarter 2019 report.Financial analysts and investors in Polygon senior secured notes are invited to participate in a telephone conference on the same day at 11:00 CET where the Q2 report will be presented. The event will be hosted by Polygon´s CFO Martin Hamner. The presentation will be held in English. Slides for the presentation will be made available on our website https://www.polygongroup.com/investors/financial-reports/ prior to the start of the conference. To participate in the telephone conference,

Lars-Inge Sjöqvist steps down from the Board of Directors of Ranplan Group AB

Lars-Inge Sjöqvist, member of the board of the Board of Directors of Ranplan Group AB since the spring of 2018 and CEO of Gapwaves AB, will step down from the Board of Directors of Ranplan Group AB.  This information is information that Ranplan Group AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set below, on 5 Aug, 2019 at 13.40 CET. For further information, please contact: Alastair Williamson, CEOTel: +44 7824 997 689alastair.williamson@ranplanwireless.comwww.

Invitation: Terveystalo H1 Result – Webcast and conference call on 8 August 2019

Terveystalo Plc will publish its half-year report for 2019 on 8 August at 9:00 EEST. (Finnish time). Materials are available after publication at: https://www.terveystalo.com/en/investors/Financial-information/ Terveystalo will host a result briefing and live webcast in English on 8 August 2019, starting at 11:00 a.m. EET, at Terveystalo Piazza, Jaakonkatu 3 B, (3rd floor), 00100 Helsinki, Finland. You can watch the webcast online at: https://terveystalo.videosync.fi/2019-q2-results To ask questions, please join the telephone conference 5–10 minutes prior to the start time using your

Ideagen launches new ‘modern, slick and visually rich’ version of Q-Pulse in 25th anniversary of the software

The latest iteration of Ideagen’s flagship product comes a quarter of a century since its launch and offers powerful dashboards and an intuitive user experienceIdeagen, the governance, risk and compliance (GRC) software provider, has launched a new version of its Q-Pulse applicaton to coincide with the 25th anniversary of the software. The UK-based firm - whihc has a global presence with sites in the UK, Europe, US, SE Asia and the UAE - unveiled Q-Pulse version 7 today (Monday, August 5th), marking the latest evolution of the popular quality, safety, risk and compliance solution. As

Akelius sells 1,492 apartments in Germany

Half in Hamburg and half in Munich.Construction years are between 1902 and 2008. Sales price EUR 420 million, corresponding to EUR 4,800 per square meter. Planned closing is end of 2019. Luther Rechtsanwaltsgesellschaft mbH and Warth & Klein Grant Thornton were Akelius’ consultants in the transaction. Pål Ahlsén, CEO:This is an additional step in operation increase rating.The sales proceeds will be used to reduce debt.Our ambition is to increase our rating from BBB to BBB+.Stockholm, 2019-08-05  Pål Ahlsén  CEO  +46 768 07 97 02  pal.ahlsen@akelius.se

SimCorp A/S – Share buyback program

Company announcement no. 35/2019 On February 20, 2019 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 12.5m, to be executed during the period from February 20, 2019 to August 22, 2019. The following transactions have been executed under the program:          Date Number of

Fellow Finance's platform facilitated 15,2 million euros of loans in July

FELLOW FINANCE PLC PRESS RELEASE 5.8.2019 at 11:45 amFellow Finance investors funded business and peer-to-peer loans worth around 15,2M€ in July. Cumulative loan volume grew over 484 million euros and the total number of investors grew to 13 509. Check the real-time peer-to-peer lending statistics on our website: www.fellowfinance.com/for-investor/statistics.  Fellow Finance Plc launched its operations in 2014 and it is an internationally active and growth-oriented FinTech group that provides crowdfunding services for people and businesses. Fellow Finance is the leading¹ Nordic loan-

Last patient recruited in Redwood Pharma Phase II trial

Redwood Pharma AB (publ) today announces that the last patient has now been included in the company's ongoing Phase II trial of RP101 and that recruitment is thus completed. RP101 is an innovative treatment for chronic dry eyes in postmenopausal women.Redwood Pharma's Phase II clinical trial is a randomized, placebo-controlled multicenter study conducted in clinics in Austria, Hungary and Germany. Approximately 100 patients are evaluated during a treatment period of three months, after which the study ends with a follow-up after the last dose has been administered. The goal is to show

Invitation to presentation of Handicare´s interim report January-June 2019

On the 14th of August at 08.00 AM (CET), Handicare will publish its interim report January-June 2019. At 10.00 AM (CET) the same day, the company holds a conference call, where President and CEO Staffan Ternström presents the report together with CFO Pernilla Lindén. After the presentation follows a Q&A session. The conference call will be held in English.The interim report and a presentation will be available on the website, www.handicaregroup.com. After the conclusion of the conference call, there will be a recording on the website. To participate in the conference, please register on the

Airport closure amounts to death sentence for thousands of sick Yemenis

Three years of restrictions imposed on Yemen’s airspace by the Saudi-led coalition is preventing thousands of sick Yemeni civilians from seeking urgent medical treatment outside the country, the Norwegian Refugee Council (NRC) and CARE said today. Sana’a airport has been closed to commercial flights since August 9, 2016. In the three years since, as many as 32,000 people may have died prematurely because they were unable to travel abroad for treatment, according to the Ministry of Health in Sana’a. NRC and CARE International have called repeatedly on the Saudi-led coalition to lift

Notification of Annual General Meeting of Clas Ohlson AB (publ)

The shareholders of Clas Ohlson AB (publ) Reg. No. 556035-8672, are hereby notified of the Annual General Meeting (“AGM”) to be held on Saturday, 7 September 2019 at 11:00 a.m. at the company’s distribution centre in Insjön, Sweden. Registration will begin at 09:45 a.m. After the AGM, light refreshments will be served. The AGM will focus on the formal matters and include less fringe arrangements than the 2018 jubilee year AGM, by reason of space limitations amongst other things.Registration and notification Shareholders who intend to participate in the AGM must: · be listed in

Navamedic is launching Alflorex in Norway

Oslo, 5th August 2019 – Navamedic ASA (OSE: NAVA) today announced the launch of Alflorex®, a unique product for irritable bowel syndrome (IBS), in Norway in September 2019. Navamedic also have the territory rights to launch Alflorex® in Denmark and Iceland.“We are pleased to announce that Navamedic is entering into the gastro therapeutic area through the first probiotic product with IBS as approved indication. Alflorex® for IBS is part of a strategic partnership with PrecisionBiotics Ltd., who is developing unique bacteria cultures that have been specifically researched and rigorously

Oboya announces earlier publication of interim report, Q2 2019

The Board of Directors of Oboya Horticulture Industries AB (publ) has decided to publish the interim report for Q2, April-June 2019 earlier than previously communicated. The interim report will be published on Friday, August 9th, 2019. Previously announced publication date was August 21th, 2019. Erik Penser Bank AB is Oboyas Certified Adviser on Nasdaq First North. Tel: + 46 8-463 83 00E-mail: certifiedadviser@penser.se For more information, please contact: Robert Wu, CEO of Oboya Horticulture Industries AB (publ) Tel: + 86 159 6983 5999Email: robert.wu@oboya.ccHomepage:

Revenio Group Corporation: Mikko Moilanen starts as the CEO of Revenio Group Corporation today

Stock Exchange Release August 5, 2019, at 10.00 am EETMIKKO MOILANEN STARTS AS THE CEO OF REVENIO GROUP TODAY M.Sc. (EE) Mikko Moilanen, will start in his position as the CEO of Revenio Group Corporation today. The previous CEO Timo Hildén continues to lead the integration work of CenterVue acquisition. Mikko Moilanen has earlier worked as the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, as the CEO of Suunto Oy and he has held several international management positions in Nokia Plc. “During the summer, I have had the pleasure of getting to know Revenio and

Pihlajalinna Plc publishes January–June 2019 Half Year Financial Report on Thursday, August 15, 2019 at 8.00 a.m.

Pihlajalinna Plc                    Investor News                     5 August 2019 at 10.00 a.m. Pihlajalinna Plc publishes January–June 2019 Half Year Financial Report on Thursday, August 15, 2019 at 8.00 a.m. Half Year Financial Report Pihlajalinna Plc will publish the Half Year Financial Report for the period January 1–June 30, 2019 on Thursday, August 15, 2019 at 8:00 a.m. (EEST). The report will be available on the company website investors.pihlajalinna.fi. Press and analyst meeting A meeting for analysts and the press, conducted in Finnish, will be held on Thursday,

GoldBlue´s New share issue registered

GoldBlue's new share issue is now registered with the Swedish Companies Registration Office. The last day for trading in GoldBlue's BTA is August 7, 2019. The exchange of BTA for shares is expected to take place on August 13, 2019. For more information please contact:Jihua Liu, Head of IREmail: ir@goldblue.euTel: +46 (0)8 559 25 266  About GoldBlue GoldBlue AB (publ) is a Swedish listed investment company within iGaming, focusing on emerging markets. GoldBlue offers players in emerging markets the latest in iGaming, powered by the latest technology, with modern user interface

Atea Denmark wins large public sector frame agreement

Staten og Kommunernes Indkøbsservice A/S (SKI), the procurement organization for the public sector in Denmark, has selected Atea as supplier on a large frame agreement for communication products. The frame agreement, called ‘50.07 Kommunikationsprodukter og -løsninger’, covers the Danish central government, 4 regions, and 73 municipalities. In addition to these government organizations that are obliged to purchase via 50.07, other public sector customers may also use the agreement on a voluntary basis. The frame agreement consists of three parts: Unified Communications and telephony,

Forxiga label updated in the EU in type-2 diabetes

5 August 2019 07:00 BST Forxiga label updated in the EU in type-2 diabetes Label updated with positive cardiovascular outcomes and renal data from the DECLARE-TIMI 58 trial AstraZeneca today announced that the European Commission has approved an update to the marketing authorisation for Forxiga (dapagliflozin) to include positive cardiovascular (CV) outcomes and renal data from the Phase III DECLARE-TIMI 58 trial in adults with type-2 diabetes (T2D). The trial enrolled a majority of patients with no existing cardiovascular disease. Mene Pangalos, Executive Vice President,

Inhalation Sciences to conduct 1 MSEK CRO study for major European pharma company

(Stockholm August 5, 2019) Inhalation Sciences (ISAB) is conducting a Contract Research Order feasibility study worth 1 MSEK for a leading European inhaled pharmaceutical developer. ISAB was chosen because of its unique ability to deliver predictive, voluminous data from tiny amounts of challenging substance in nebulized as well as dry powder aerosol.“Few tests are more crucial in an inhaled drug’s lifetime than pre-clinical feasibility studies” says ISAB CEO Lena Heffler. “With a typical drug costing on average 2.6 BUSD to develop, being able to minimize errors and generate predictive data

YIT to participate in two dam projects in Norway

YIT Corporation Press release, August 5, 2019, at 08:30 a.m.YIT will build a new dam on Lake Mjåvatn to replace the old dam built in the 1940s and repair the Kuli Dam that was built in the mid-1960s. YIT will build a new dam for E-CO Energi in the municipality of Ål in Southern Norway. The new dam will replace the old dam from the 1940s on Lake Mjåvatn and will be located below the old dam. In addition to building the dam, YIT will also excavate a tunnel in the area that is about 500 metres long. The new dam will be approximately 100 metres long and 11 metres high at the highest point.

Share buy-backs in Telia Company during week 31 2019

During the period July 29, 2019, until August 2, 2019, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 2,645,399 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back program that Telia Company announced on April 16, 2019. The share buy-back program, which runs between April 16, 2019, and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period July 29,

The Board of Directors of Cxense ASA unanimously recommends a voluntary cash offer from Piano Software, Inc. to acquire all of the shares of Cxense.

Oslo, August 5, 2019, The Board of Directors of Cxense ASA (“Cxense”; OSE ticker code: “CXENSE”) announces an agreement with Piano Software, Inc. (“Piano”) whereby a subsidiary of Piano, Piano Software B.V. (under incorporation) (the "Offeror") will offer to acquire all of the shares of Cxense through a voluntary cash offer of NOK 16.00 per share. The Board of Directors of Cxense unanimously recommends the shareholders of Cxense to accept the offer. The consideration offered will be NOK 16.00 in cash per Cxense share (the “Offer Price”), which represents a premium of approximately 152%

KONE wins order to equip Central Boulevard Towers, a mixed-use development in Singapore

KONE Corporation, press release, August 5, 2019KONE Corporation, a global leader in the elevator and escalator industry, has secured an order to deliver a total of 47 elevators and escalators to Central Boulevard Towers mixed-use development. The complex will be equipped with KONE’s groundbreaking innovations including the KONE UltraRope® hoisting technology and the intelligent KONE 24/7 Connected Services.Located in Singapore’s Central Business District and developed by Wealthy Link Pte Ltd (a subsidiary of IOI Properties), Central Boulevard Towers will consist of premium Grade

There are no items matching the current filter
There are no more items matching the current filter
Back to top